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Abstract
The success of antiretroviral therapy (ART) programmes requires high adherence and retention in
care. In light of healthcare shortages, group interventions may be optimal ways to deliver
information and provide support to ART patients. This study assessed the acceptability of a group
intervention for patients and their supporters, which aimed to decrease stigma, harness social
support and improve adherence. 28 ART patients attended a four-hour group intervention and 11
brought someone they identified as a potential supporter. The intervention was led by HIV-
infected facilitators and included interactive sessions on HIV, ART, caregiving, stigma and
disclosure. Participants completed intake and exit interviews and participated in focus group
discussions. Participants rated the intervention favourably and in FGDs patients said they gained
knowledge about adherence, felt empowered to tackle stigma and disclose, and experienced
reductions in loneliness. Supporters reported they learned how to provide better care, gained
knowledge, and felt closer to the person they were taking care of. Both patients and supporters
saw HIV-infected facilitators as role models. Opinions were mixed about benefits of combining
patients and supporters in the same intervention due to confidentiality. The group intervention
showed potential to reduce stigma, increase social support, and improve adherence to therapy.
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Background
HIV is a major health concern in Tanzania, where an estimated 6.6% of women and 4.6% of
men are HIV serpositive (Measure DHS 2008). In response to the increasing burden of HIV,
the Tanzanian National AIDS Control Programme provides free antiretroviral therapy
(ART) in government-coordinated care and treatment centres (CTC’s) across the country. At
the most recent estimate, approximately 235,012 people were receiving ART and 454,681
were enrolled in HIV care, representing 21.5% of the estimated 2.1 million people living
with HIV/AIDS in the country (Tanzanian National AIDS Control Programme 2009). As
access to antiretroviral therapy (ART) expands to meet the need, and people are




Glob Public Health. Author manuscript; available in PMC 2012 December 26.
Published in final edited form as:










therapy and improve the quality of life of those who are infected. Such efforts must take into
account the already stretched health care system, which is limited in its ability to provide
high-quality care for all ART patients that need it (Hanson et al. 2009).
Proper adherence to ART regimens is imperative to maximise therapeutic success and avoid
drug resistance (Nieuwkerk et al. 2005, Bangsberg 2006, Bangsberg 2008). However,
approximately 23% of patients in sub-Saharan Africa do not meet proper treatment
adherence criteria (Mills et al. 2006b), and adherence to therapy and continuation in care
often decreases over time (Howard et al. 2002, Aboubacrine et al. 2007, Rosen et al. 2007).
It is generally agreed that patients need to maintain at least 95% adherence in order to
minimize risk of virological failure (Paterson et al. 2000, Bangsberg 2006). For patients
taking a twice-a-day drug regimen, 95% adherence translates into missing no more than one
pill every 10 days. The challenges of maintaining high levels of adherence have been
documented in both North America and sub-Saharan Africa (Mills et al. 2006a, Mills et al.
2006b), including Tanzania (Hardon et al. 2006, Hardon et al. 2007, Ramadhani et al. 2007,
Watt et al. 2010) In addition, retention in care has proven to be a challenge in African
settings (Rosen et al. 2007), including Tanzania (Roura et al. 2009, Wringe et al. 2009).
Stigma (Mahajan et al. 2008, Visser et al. 2009), disclosure (Ramadhani et al. 2007, Greeff
et al. 2008, King et al. 2008, Mayfield Arnold et al. 2008) and lack of social support
(DiMatteo 2004, Murphy et al. 2004) are important factors that impact HIV patients’
adherence to therapy and retention in care. HIV-related stigma is prevalent in Tanzania
(Genberg et al. 2009) and is associated with low social support and limited HIV disclosure
(Khumalo-Sakutukwa et al. 2008). HIV related stigma stems in part from fear of death, fear
of the burden of caring for HIV infected patients, and fear of transmission of HIV (Maman
et al. 2009). Reducing both perceived and experienced stigma can lead to HIV disclosure
and the harnessing of social support, which in turn can facilitate adherence through
reminders to take medication, provision of food and money, and emotional encouragement
(Kumarasamy et al. 2005, Bikaako-Kajura et al. 2006, Watt et al. 2009). Additionally, social
support is important for mitigating negative psychological sequelae from an HIV diagnosis
and meeting financial obligations (Holmes et al. 2007).
Models for adherence interventions in higher resource countries such as the United States
often rely on intensive individual counselling by trained professionals, telephone follow up,
or mechanisms such as pagers or financial incentives (Haddad et al. 2000, Simoni et al.
2003, Cote et al. 2005, Simoni et al. 2008). In developing country settings, where limited
financial and human resources do not permit such intensive interventions, a community-
based approach that pairs ART patients with lay counsellors is often used to promote
patients’ adherence (Behforouz et al. 2004, Coetzee et al. 2004, Koenig et al. 2004).
However, such interventions continue to be individual and long-term in nature, and therefore
face challenges in reaching all the patients who might benefit.
In light of the importance of sustaining adherence to ART, and the influence of stigma and
social support on adherence outcomes, we developed and examined the acceptability of a
group intervention addressing these issues for new ART patients in Arusha, Tanzania. In
particular, we were interested in 1) whether new ART initiates would attend a group
intervention outside of clinic hours, 2) whether they would choose to bring a treatment
supporter with them, and 3) how the intervention would be perceived as addressing the
needs of ART initiates and their treatment supporters in this setting. The findings help to
identify important components for cost effective interventions to support the growing
number of people starting ART in Tanzania and beyond.
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Description of the intervention
The aim of the intervention was to support longer, healthier lives for people living with HIV,
specifically by decreasing HIV related stigma, increasing social support, and therefore
improving adherence to ART (Figure 1). To inform the intervention, we conducted four
focus group discussions (FGDs) with ART patients (selected based on participation in prior
research), family members of ART patients (identified through the patient participants),
health care providers (including all providers at the study clinic who provided direct care to
ART patients), and HIV infected counsellors (all employed at the study clinic). The FGDs
were facilitated by the last author (MJ), were transcribed in Kiswahili and translated into
English. Themes were identified by closely reading the transcripts and highlighting topics to
be covered in the intervention, issues of administration, and potential barriers for attendance.
The FGDs suggested that new ART patients required information on the following: basic
information about ART and how to use the medication, adherence, clinical care, healthy
living, diet and nutrition, sexual activity, psychological issues, social support, disclosure and
stigma. In addition, data suggested that treatment supporters of patients also required
information about those topics, as well as specific information about meeting the physical
and emotional needs of someone who is HIV infected and taking ART, and communicating
effectively about HIV. The FGDs identified potential barriers to participation in an
intervention, including transportation money, lack of time, and fear of stigma and
involuntary disclosure. It was suggested that HIV-positive facilitators would best deliver the
intervention, as a way to mitigate potential stigma and open up more honest discussions.
Based on the themes that emerged from the FGDs, the authors worked together with the two
identified facilitators (described below) to develop a four-hour group intervention for
patients beginning ART, along with their self-selected treatment supporter (e.g., a family
member or friend). The intervention focused on new ART initiates (taking ART for less than
six months) because prior research we conducted (Watt et al. 2009) pointed to the
importance of the initial treatment period for gaining skills and knowledge that would allow
patients to succeed on ART.
The intervention, entitled “Zinduka”, Kiswahili for “stand up/wake up,” was developed in
concordance with the social cognitive theory, which suggests that new behaviours and skills
are best learned through observation and role playing (Baranowski et al. 2002). Two
facilitators led the intervention, which included content on the basics about HIV and ART,
caring for someone taking ART, stigma and disclosure. Role plays were used to create a safe
environment for participants to learn communication and behavioural skills related to living
with HIV and taking ART, and to facilitate open dialogue between patients and their
supporters. The intervention was written up into a brief manual, which included all activities
and a sample script for the facilitators, and it was translated into Kiswahili by the last author
(MJ).
The two facilitators of the intervention were HIV infected individuals who were already
active in the clinic and community as voluntary adherence counsellors (VACs). The VACs
are trained by the clinic to provide support to ART patients in adhering to their medication.
They receive a modest stipend from the clinic and are available to meet with patients during
HIV clinic days and through home visits. The fact that the facilitators were living with HIV
and taking ART from the study clinic meant that they could answer questions about what to
expect over time and could provide insight into negotiating care at the clinic. Using HIV
infected facilitators was also intended to provide a role model for living a positive and
healthy life with HIV. The facilitators we chose had a secondary school education, were
proficient in both Kiswahili and English, and had experience conducting workshops and
making public presentations about HIV. They had substantial input into the development of
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the intervention, and received ongoing training on the content and delivery of the
intervention, including several practice sessions.
Study site
The study was conducted in 2007 at a government supported faith based clinic in Arusha,
Tanzania. The study clinic began offering ART in 2003 (at cost), and has offered free ART
since 2004, funded by the United States Presidents Emergency Plan for AIDS Relief
(PEPFAR). Patients are eligible for free ART from the study clinic if they have a CD4 count
of less than 200 cells/mL or WHO clinical stage IV disease. The vast majority of ART
patients at the time were prescribed Triomune (manufactured by Cipla in Mumbai, India), a
twice-a-day single combination ART pill containing stavudine, lamivudine and nevirapine.
Prior to beginning ART, patients meet with a qualified HIV counsellor for approximately 10
minutes to discuss ART treatment and potential side effects. Additionally, the clinic paired
patients with one of 15 HIV infected lay counsellors (VAC’s), who were tasked with
providing emotional and informational support to patients by making at least one visit to
their homes and being available to meet with them during clinic hours. At the time of the
study, the clinic was following over 1100 patients on ART and employed two doctors and
two counsellors to provide ART-related services. Conversations with clinic management and
providers prior to the study implementation revealed concerns about inconsistencies in the
quality and quantity of information and support provided to ART initiates, and a perception
that these challenges would increase as the ranks of ART patients continued to grow at the
clinic.
Methods
During two distinct one-week periods, all patients (n=37) presenting at the study clinic who
had been taking ART for fewer than six months were invited to participate in the study.
Clinic counsellors identified eligible patients and referred them to a study recruiter. Potential
participants were informed about the study, and, if they provided consent, were asked basic
demographic questions including level of education, employment status, travel time to the
clinic, modes of transportation used, and disclosure of HIV status. Pharmacy records were
used to confirm age and start date of ART. Participants were given an invitation to an
intervention the following Saturday, as well as an invitation to bring a treatment supporter of
their choice. They were told that a treatment supporter was a family member or friend who
knew about their HIV status and provided, or had the potential to provide, support to help
them live positively with HIV.
On the day of the intervention, treatment supporters completed intake interviews to collect
demographic information, and both ART patients and treatment supporters completed exit
interviews, which included questions about what participants learned from the intervention
and feedback to improve the intervention. Follow up phone calls were made to those who
agreed to participate in the study but did not attend the intervention, in order to assess
barriers for attendance. The second author (EA) and the last author (MJ) attended both
intervention sessions to collect quality assurance data, including whether all 20 sub-sections
of the intervention were covered in their entirety. All participants received compensation
estimated to cover transportation costs to and from the group intervention (approximately
$2).
Upon leaving the intervention, both groups of participants (ART patients and their treatment
supporters) were invited to return later in the week to participate in a focus group discussion
(FGD). Five FGDs were conducted, three for patients and two for those who attended the
intervention as treatments supporters. The FGDs followed a semi-structured interview guide
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to elicit detailed feedback about the intervention, including how the intervention changed
their perceptions of HIV and ART; how participants felt about the group setting and the
engagement of treatment supporters in the program; and what recommendations they would
have for revising the intervention. Each group lasted between 60 and 90 minutes, and
participants received compensation for their time and transportation (approximately $2).
Six Tanzanian interviewers were trained to recruit patients and administer the research
instruments. Half were female and four were living with HIV. The Tanzanian study
coordinator (last author, MJ), who had specific training in qualitative methods, conducted all
of the FGDs, together with a note taker. Demographic surveys, intake surveys and exit
interviews were entered into Excel and basic frequencies were analyzed. The FGDs were
audiorecorded, transcribed in Kiswahili, and translated into English. The first two authors
(MW and EA) analyzed the focus group data through multiple readings of the transcripts
and identification of common themes and patterns, until consensus was achieved. The data
were further examined and summarized through descriptive text-based summaries and data
display matrices (Miles et al. 1994). Representative, verbatim quotes were selected to
illustrate key findings.
The study had IRB approval from the UNC School of Public Health and the Tanzanian
Institute for Medical Research.
Results
Demographics
Of 37 recruited patients, 28 (76%) attended the intervention and 11 (39%) brought
supporters (Figure 2). Of the nine patients who did not attend, only four could be reached by
telephone. Reasons given for non-attendance included fear of HIV-related stigma (n=2) and
time conflict (n=2). Participating patients included 21 women and seven men, with a mean
age of 37.6 years. Participants had been taking ART between one and six months, with an
average time on ART of 3.3 months. Seven (19%) had not disclosed to anyone at the time of
recruitment. Only 13.8% of the participants had education beyond primary school, and 8%
reported having paid employment. Quality assurance data revealed that the intervention was
delivered as intended in the manual, with all 20 sections covered with participants in each
session.
A total of 23 patients (82%) and 11 treatment supporters (100%) participated in focus group
discussions following the interventions.
Exit interviews
During exit interviews, both patients and supporters rated the usefulness of the intervention
in its entirety and divided into specific components. When asked to rate the intervention
numerically on a scale of 1–5, ratings were overall favourable (Table 1). Both patients and
treatment supporters gave the highest overall rating to “gaining information on ART.”
Focus group discussions
Qualitative findings revealed key benefits of the intervention, in particular that the
intervention increased social support, reduced loneliness, helped participants to see HIV as a
“normal disease”, and reduced both internalized and externalized stigma. In addition,
participants reported that they appreciated the opportunity to learn necessary information
about ART and correct rumours, which for the supporters alleviated their hesitation in caring
for someone living with HIV.
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Reductions in stigma and loneliness through normalizing HIV—Both patients
and supporters talked about how the intervention helped them to see HIV as a normal
disease that affected many people, and that it therefore reduced their own perceptions of
HIV stigma. This came in large part through the group setting, which facilitated interacting
with others who were HIV infected.
It helped me to see this problem as any other normal problem and I got new ideas
of living positively. It helped me reduce worries after seeing that this is a problem
that a lot of people are concerned with. (Female patient on ART)
Treatment supporters similarly reported that the intervention helped to normalize the
disease, which in turn increased their confidence to provide effective support.
This seminar will enable us to help our patients effectively. And it has helped us to
see the patient as a normal person. (Male supporter)
Participants felt that the intervention reduced both their perceived and internalized stigma,
which can be detrimental to positive living with ART. This impact on alleviating stigma was
in large part due to the presence of healthy, confident facilitators who were open about their
HIV, as this participant pointed out:
First, we are so grateful that even the facilitators have the problem the same as
ours, and are the people who are very much experienced about living positively and
they have used ARTs for a long time. This encourages us that we can live longer
like our facilitators. (Female patient on ART)
Treatment supporters also reported benefits from their exposure to the facilitators,
conveying that it challenged their notions about the association between HIV and death.
Once, a lot of people were despaired that if you get this problem then that’s your
end, but after attending the seminar you find that you can continue to live. (Female
supporter)
Benefits of the intervention for adherence—Participants talked about how the
intervention provided important information about ART and adherence, and in particular
that it helped to correct prior misconceptions. In some cases, patients had not previously
grasped the importance of taking the pill every day at the same time, and in other cases, they
had heard that it was essential to take the pill at the same time, but this was taken to a
detrimental extreme.
I was taking my pills at 8:00 and even 20 minutes after the time I was not taking
it… I was skipping until the next dose. But after the seminar I learned that you can
still take your pill if you forgot. (Female patient on ART)
The seminar therefore helped patients to understand the important principle of adherence,
but to hone their own judgement about having some flexibility, and importantly to feel
empowered to seek advice from a health care provider or counsellor if they had questions
related to adherence. The intervention also helped to correct misunderstandings that one
would eventually be able to stop taking ART; that ART will stop working after a few years;
and that taking ART will lead to an earlier death.
Through the role plays and discussions in the intervention, participants said they learned
strategies to facilitate consistent use of ART. These strategies included finding a private
place to take their pills if a neighbour or friend was visiting who didn’t know about their
infection, and using a calendar to track pill taking and reduce the chance of taking more pills
than prescribed. Treatment supporters also reported learning the importance of reminding
patients to take their pills on time.
Watt et al. Page 6










Additionally, participants said the intervention made them generally more comfortable with
the idea of taking ART, because of both a realization that the medication will improve their
health and prolong their lives, and a perception that they are not alone in taking ART. As
people felt more comfortable with the idea of taking ART, they also felt more motivated to
take the pills correctly and consistently.
When I came to this seminar I learned about these pills, that if I will use it, it will
help me. Because [before] I was not trusting these pills. (Female patient on ART)
When I took these pills on the first day I cried a lot. But when I came to this
seminar I see it’s normal, there are a lot of people who use the pills. (Female
patient on ART)
Balancing need for social support and fear of disclosure—The majority of
participants (76% of patients and 91% of supporters) were in support of an intervention
format that combined both patients and their supporters. Those who expressed that they did
not feel comfortable with a combined seminar were concerned with confidentiality and
involuntary disclosure of their HIV status in the larger community.
In support of a group seminar that combined patients and supporters, participants suggested
that the group setting reduced a sense of loneliness, as illustrated by this woman:
I was really comforted after seeing live the people who have lived many years with
HIV. (Female patient on ART)
By coming together that helped us to see this problem is the problem of all.
(Female supporter)
Participants also recognized that combining patients and supporters had a benefit of bringing
patients and their supporters closer together, and sharing information that could later be
reinforced in the home environment.
It would be very hard to come into agreement if everybody [patients and
supporters] attended different seminars. But when you are together, you remind
each other of what you learned… By attending the seminar together, it brings you
closer, and even if he gets any problem it becomes easy for you to help him,
because you know what you’re supposed to do. (Male supporter)
On the other hand, some participants suggested that a group setting introduced the fear of
breaches in confidentiality and involuntary disclosure of patients’ HIV status in the broader
community, as expressed by both a patient and a supporter.
They have to have their own day [intervention], because I think they won’t keep the
secret to people in the streets. This is different for us as patients because we have
the same problem then we can keep each other’s secret. (Female patient on ART)
But because of the need of secrets, it seems more important to attend different
groups, because not all the treatment supporters can keep the secret of other
patients. (Male supporter)
The intervention not only provided skills to disclose, but also provided positive models for
disclosure by seeing patients together with their supporters. In one FGD, a patient who had
not brought a treatment supporter to the intervention revealed that the intervention had
encouraged her to disclose her HIV status to a relative for the first time in the days following
the intervention.
Supporters remarked on benefiting from the group setting, which provided an opportunity to
show support for their friend of family member taking ART. In the FGDs during the
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intervention development, supporters expressed feeling helpless on how to be of most
comfort and help to their loved ones, so the intervention provided concrete ways for them to
express and offer support, and opened up dialogue between patients and supporters, as
expressed by these participants.
Actually, we were very happy, because we took the occasion to comfort them.
(Female supporter)
It was an important occasion of showing great love. (Female supporter)
Discussion
Adherence to therapy (Mills et al. 2006b) and retention in care (Rosen et al. 2007) pose
significant challenges to the scale-up of ART programs in sub-Saharan Africa. Providing
adequate and consistent information and support to new ART initiates is essential to meet
this challenge, but may be hampered due to shortages of health care providers and growing
ranks of ART patients. A brief group intervention for ART initiates and their treatment
supporters offers a likely cost-effective means to prepare patients for lifetime ART use, to
increase social support, and to address psychosocial issues such as disclosure and stigma. In
this study, we developed such an intervention and demonstrated its acceptability in a
Tanzanian setting.
Prior to study implementation, clinic staff and counsellors were rightfully concerned about
whether patients would attend a group intervention and whether they would invite and bring
a treatment supporter. They noted patients’ fears of making their HIV status public and the
logistical challenges that may interfere with their coming to the clinic on a weekend.
However, high attendance rates (76% of those recruited) and the fact that a large proportion
of patient attendees (39%) brought a treatment supporter confirmed that a group intervention
such as this, offered outside of clinic hours, is acceptable in this setting.
Participants reported that they gained important and useful knowledge from the intervention,
which indicates that the information was clearly presented and relevant to participants’ lives.
In a low resource setting where trained health care providers are in short supply (Naicker et
al. 2009), delivering this information in a consistent way in a group environment can ensure
that all new patients and their supporters receive information necessary for them to
effectively understand and manage their HIV infection and initiation onto therapy.
Perhaps even more importantly than delivering information, the intervention structure
helped to normalize HIV infection, and in turn had an impact on both self stigma and
perceived stigma. The benefits of group interventions on psychosocial factors among HIV
infected people have been documented elsewhere (Hyde et al. 2005). In this setting, there
was evidence that engaging HIV infected role models helped to reduce internalized shame
and stigma and facilitate HIV disclosure. The inclusion of treatment supporters and patients
in the same intervention resulted in mixed feedback. While both groups pointed to the
advantages of harnessing and strengthening patients’ social support, there was also an
expressed concern that the group setting may compromise the confidentiality of participants’
HIV status. Although the majority found that the benefits of a group setting outweighed any
potential risks, future studies may explore potential advantages of segregated interventions
or an option to choose either combined or separate groups.
The targeting of the intervention to patients who are initiating ART has significant
advantages. The first few months of initiating ART requires additional information and
support to navigate care, manage side effects and develop a routine for medication
adherence. By conducting an intervention during the early stages of ART treatment, there is
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the potential to expedite the process of disclosure, which can lead to acquiring the social
support and tools needed to adhere to medication and remain in care (Watt et al. 2009).
We found that using HIV infected facilitators was a particular advantage of this intervention.
HIV infected counsellors as mentors and role models have been used by community-based
organizations since the beginning of the epidemic, but few interventions have evaluated their
impact (Simoni et al. 2007). In this setting, the fact that the facilitators were already engaged
in providing care at the study site made their participation even more effective. The two
facilitators we used had secondary school education and previous experience leading groups
for HIV infected people. Although we did not follow participants over time, it is possible
that some participants may have had follow up with the facilitators in the months after the
intervention, since the facilitators were always present during HIV clinic days at the study
site. Although not measured or reported, engaging HIV infected individuals as facilitators
and research assistants may have had added benefit for those individuals themselves in
building their skill set and helping them to become stronger advocates for HIV in their
communities.
This study was limited by several factors, including a short time period, small sample size,
single study site, participant self-selection, and lack of behaviour change data. The number
of participants who were eligible to participate in the study but chose not to be referred to
the study coordinator was not documented, although referring counsellors anecdotally said
that a small handful of people chose not to be referred because they lacked time on their
appointment day. Not having data about referral refusals over-estimates our uptake of the
intervention, and provides an indication that the intervention may not be appealing or
feasible for certain groups (e.g., those with employment or other regular responsibilities).
Additionally, there were 5 patient participants (out of 28) who did not attend a FGD to give
feedback on the intervention. It is possible that those who did not attend a FGD were people
who were less satisfied with, or less invested in, the intervention, which may therefore bias
our conclusions about its acceptability. The intervention was piloted in a relatively small,
faith-based clinic, which offered important support systems for patients, including individual
counselling and pairing with an HIV-infected peer counsellor. It is possible that the
observed feasibility and acceptability was in part a factor of the setting, and that the results
would not be replicated in other settings, in particular large public clinics with a less
personal nature.
Conclusions
Despite its limitations, the study points to the potential acceptability and feasibility of a
group intervention for new ART initiates and their treatment supporters in a low resource
setting, facilitated by HIV positive individuals. The high rate of attendance and positive
assessments from both patients and their supporters are encouraging and suggest the need
for a more rigorous evaluation of such an intervention. Further research may consider the
added value of a multi-session intervention, although it should keep in mind the cost and
feasibility of the intervention format for scale up. Future studies should also explore the
most appropriate stage of treatment for patients to attend such an intervention, and whether
patients and supporters should be included in the same or different groups.
As the number of people taking ART in low-resource settings continues to increase, and
additional pressures are put on already stretched health care systems, it is imperative that we
identify low-cost and feasible interventions to ensure that ART initiates have adequate
information and support to retain them in care and bolster their adherence to therapy. A brief
group intervention that involves ART patients and their treatment supporters and is
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facilitated by HIV infected lay counsellors may meet this need and should be evaluated
further.
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Table 1
Participants’ ratings of the seminar on a scale of 1 (lowest) to 5 (highest) (n=39)
Usefulness of seminar (by topic)
Patients Treatment supporters
Mean S.D. Mean S.D.
Overall 4.76 0.56 4.27 1.19
Information on HIV 4.68 0.71 4.55 0.69
Information on ART 4.90 0.50 4.45 0.82
Information on use of ART 4.76 0.47 -- --
How to overcome stigma 4.66 0.67 -- --
How to talk to others on their HIV status 4.24 1.20 -- --
How to support someone who is HIV infected -- -- 3.82 1.33
How to support someone to adhere -- -- 4.36 1.03
How to support patients to live positively -- -- 3.64 1.01
How to support someone to disclose -- -- 4.09 0.83
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